Ripley94
10 Jan 2020
COULD BE A BIG BIG DAY! SAR… XXXX 24% rise today now 0.47p
techno-foxx
09 Dec 2019
Latest on drug trials [link]
Ripley94
27 Aug 2019
COULD BE A BIG BIG DAY! SAR… XXXX Dropped to 0.27p on 9th August . 0.32p today .
techno-foxx
24 Jul 2019
Latest on drug trials a massive share consolidation must now be on the cards now we have 3 billion shares in issue?
Ripley94
16 Jul 2019
COULD BE A BIG BIG DAY! SAR… XXXX Been watching it since offer did not lift on ( D ) on various occasions since. Sold some UJO on Friday and used to pick some up @ 0.398p this morning ( Tuesday ) ( S i ) + 75 % deal .
Ripley94
26 Jun 2019
8 % Gain on news SAR… XXXXX looks like first post on this one i see a first buy 15 June 2015 @ 0.25 ??
Ripley94
26 Jun 2019
Certainly not worth selling SAR… XXXX Just had a look and see my last sell was in ( D ) on 24th April 2016 , none left there. First box " all multi " This last post of 5th April might refer to ( X ) Not a large holding it appears .
Ripley94
25 Jun 2019
COULD BE A BIG BIG DAY! S A R… XXXX Primary bid offer… not good news. Mainly offer rubbish. Wish I’d not heared of them lol. 27 % discount and e I s eligible???
techno-foxx
05 Jun 2019
Latest on drug trials extract from other articles on latest trial results Of note, we have recently received management support from a major immuno-oncology company to potentially supply their leading immunotherapeutic agent to run a combination study with SRA737. We will further analyze these opportunities and evaluate next steps with this asset over the coming months, exploring options to enable the continued advancement of SRA737 in the context of our emerging pipeline."
techno-foxx
03 Jun 2019
Latest on drug trials looks like FDA approval now a slam dunk, unmet need [link]
techno-foxx
03 Apr 2019
Well worth reading Proactiveinvestors UK Sareum’s flagship Chk1 inhibitor shows serious lung cancer potential in mouse... Sareum Holdings Plc (LON:SAR) - After 50 days, eight out of ten mice achieved a complete response, which means there was no detectable sign of cancer anymore
techno-foxx
04 Mar 2019
Another 200% up.... Proactiveinvestors UK Sareum boss “very pleased†with progress of flagship Chk1 inhibitor Sareum Holdings Plc (LON:SAR) - US firm Sierra Oncology has licensed the molecule and the results from two early-stage ovarian cancer studies are due in the current half
techno-foxx
03 Mar 2019
Another 200% up.... I posted this on two sites oxford biomedical and on this board as I thought this would be a perfect fit for a NEW cancer bomb to target solid cancers alongside CTL019? Is this the perfect partner to CTL019 Market Discussions Oxford BioMedica (lse
xb) Feb 2017 1 / 3 Feb 2017 Feb 2017 techno_foxx Feb '17 Techno fox Is Sareum Checkpoint Kinase 1 (Chk1) Oral drug the perfect partner to CTL019? I am an investor in both Oxford Biomedica and Sareum, although i have no scientific background in the science behind this drug, i believe if the drug trials does what it says on the tin, its future could be massive, i came up on this drug and Saraum whilst researching immunotherapy or immuno-oncology therapies, these new wonder treatments such as CTL019 are in deed wonder drugs that have re-engineered a patient’s own blood cells to turbo charge the bodies own immune system to seek out and kill tiny cancer cells in the blood and once injected they can carry on working for decades, however this treatment has only one achilles heel and that is solid tumors, if caught early enough before a tumor has formed it can wipe out any and all traces of cancer, however once a tumor has formed and mutated into a solid lump it becomes very difficult for these newly engineered and introduced blood to attack these solid tumors, so i started looking to see if there existed another way of overcoming this problem to create the perfect cancer bomb, so i started looking for drugs and therapies that directly targeted cancer tumors, it was whilst researching this whole area that i stumbled on sareum and their jointly developed oral drug with cancer research UK Checkpoint Kinase 1 (Chk1), I just want to stress again i am no expert, but what i am good at is joining up the dots and seeing things other people might have missed, whilst all the talk on the use of this drug is in combination with chemotherapy, i believe it?s real promise might well be alongside the latest and most exciting immuno-oncology therapies, targeting the hard to reach solid tumors, as it works by preventing the solid tumors from mutating, dividing or growing i was just wondering if it was possible to take this oral drug for the long term because if it effectively puts the solid tumors growth into a long term sleep or hibernation mode from which it never wake up from when used in combination with any or all immuno-oncology therapies. Extract from today?s RNS Checkpoint Kinase 1 (Chk1) Targeting lung, pancreatic and other cancers, licensed to Sierra Oncology This programme was successfully licensed to Sierra Oncology (NASDAQ:SRRA) in September 2016. The handover of the running of the two ongoing clinical trials was completed in January 2017, resulting in a $2 million milestone payment by Sierra, of which Sareum will receive approximately £450k. Additional payments in the aggregate amount of up to US$319.5 million become payable upon achievement of certain development, regulatory and commercial milestones. Sierra Oncology will also owe high single to low double digit royalties on the net sales of any product successfully developed. Sareum would be entitled to 27.5% of any such payments. The Phase I clinical trials in cancer patients initially opened at the Royal Marsden Hospital, London in May 2016 and, since then, two other centres have started to recruit patients; the Velindre Cancer Centre, Cardiff and the Freeman Hospital, Newcastle. Sierra Oncology has recently announced that it expects to issue an update on these trials towards the end of 2017. It also notes that it is considering further trials of SRA737 in combination with targeted and immuno-oncology therapies, and expects to report preclinical data on these combination studies during the second half of 2017. Checkpoint Kinase 1 (Chk1) Market Discussions Sareum Holdings (lse:sar) Feb 2017 1 / 1 Feb 2017 Feb 2017 techno_foxx Feb '17 Techno fox I am an investor in both oxford biomedica and Sareum, although i have no scientific background in the science behind this drug, i believe if the drug trials does what it says on the tin, its future could be massive, i came up on this drug and Saraum whilst researching immunotherapy or immuno-oncology therapies, these new wonder such as CTL019 are in deed wonder drugs that have re-engineered a patient’s own blood cells to turbo charge the bodies own immune system to seek out and kill tiny cancer cells in the blood and once injected they can carry on working for decades, however this treatment has only one achilles heel and the is solid tumors if caught early enough before a tumor has formed it can wipe out any and all traces of cancer, however once a tumor has formed and mutated into a solid lump it becomes very difficult for these newly engineered and introduced blood to attack these solid tumors, so i started looking to see if there existed another way of overcoming this problem to create the perfect cancer bomb, so i started looking for drugs and therapies that directly targeted cancer tumors, it was whilst researching this whole area that i stumbled on sareum and their jointly developed oral drug with cancer research UK Checkpoint Kinase 1 (Chk1), I just want to stress again i am no expert, but what i am good at is joining up the dots and seeing things other people might have missed, whilst all the talk on the use of this drug is in combination with chemotherapy, i believe it?s real promise might well be alongside the latest and most exciting immuno-oncology therapies, targeting the hard to reach solid tumors, as it works by preventing the solid tumors from mutating, dividing or growing i was just wondering if it was possible to take this oral drug for the long term because if it effectively puts the solid tumors growth into a long term sleep or hibernation mode from which it never wake up from when used in combination with any or all immuno-oncology therapies. Extract from today?s RNS Checkpoint Kinase 1 (Chk1) Targeting lung, pancreatic and other cancers, licensed to Sierra Oncology This programme was successfully licensed to Sierra Oncology (NASDAQ:SRRA) in September 2016. The handover of the running of the two ongoing clinical trials was completed in January 2017, resulting in a $2 million milestone payment by Sierra, of which Sareum will receive approximately £450k. Additional payments in the aggregate amount of up to US$319.5 million become payable upon achievement of certain development, regulatory and commercial milestones. Sierra Oncology will also owe high single to low double digit royalties on the net sales of any product successfully developed. Sareum would be entitled to 27.5% of any such payments. The Phase I clinical trials in cancer patients initially opened at the Royal Marsden Hospital, London in May 2016 and, since then, two other centres have started to recruit patients; the Velindre Cancer Centre, Cardiff and the Freeman Hospital, Newcastle. Sierra Oncology has recently announced that it expects to issue an update on these trials towards the end of 2017. It also notes that it is considering further trials of SRA737 in combination with targeted and immuno-oncology therapies, and expects to report preclinical data on these combination studies during the second half of 2017.
Ripley94
02 Mar 2019
Another 200% up.... Hi techno-foxx I could not see that in you activity please give more detail .
techno-foxx
01 Mar 2019
Another 200% up.... Re last RNS You might want to re-read my post dated Feb 2017 Checkpoint Kinase 1 (Chk1) ï„‘
